Coherus BioSciences Inc (CHRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Coherus BioSciences Inc (CHRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH410367D
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Coherus BioSciences Inc (Coherus BioSciences) formerly known as BioGenerics Inc is a biosimilar platform company that develops and commercializes biosimilar drugs. The company's pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate,which is being developed to treat crohn's disease, ulcerative colitis, and psoriasis arthritis, among others. Coherus BioSciences capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus BioSciences is headquartered in Redwood City, California, the US.

Coherus BioSciences Inc (CHRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Coherus BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Coherus BioSciences Raises USD55 Million in Series C Venture Financing 12

Coherus BioSciences Raises USD28 Million In Venture Financing 13

Coherus BioSciences Raises USD46.3 Million In Venture Financing 14

Partnerships 14

Baxter Amends Co-Development Agreement with Coherus Biosciences 14

Baxter International Enters Into Co-Development Agreement With Coherus Biosciences 15

Licensing Agreements 16

Coherus BioSciences Enters into Licensing Agreement with Genentech 16

Coherus BioSciences Enters into Licensing Agreement with Selexis 17

Orox Pharma Enters into Licensing Agreement with Coherus BioSciences 18

Coherus BioSciences Enters Into Licensing Agreement With Daiichi Sankyo For Biosimilars 19

Equity Offering 20

Coherus Biosciences Prices Public Offering of Shares for USD125 Million 20

Coherus Biosciences Plans to Raise up to USD100 Million in Public Offering of Shares 22

Coherus BioSciences Prices Public Offering of Shares for USD63 Million 23

Coherus BioSciences Raises USD10 Million in Private Placement of Shares 24

Coherus BioSciences Prices Public Offering of Shares for USD120 Million 25

Coherus BioSciences Raises USD92 Million in IPO of Shares 26

Coherus BioSciences Raises USD2.5 Million in Private Placement of Shares 28

Coherus BioSciences Receives Equity Investment from MX II Associate 28

Debt Offering 29

Coherus BioSciences Raises USD100 Million in Private Placement of 8.2% Notes Due 2022 29

Coherus BioSciences Inc-Key Competitors 31

Key Employees 32

Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

May 08, 2017: Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results 34

Mar 13, 2017: Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results 36

Nov 09, 2016: Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results 38

Aug 09, 2016: Coherus Biosciences Reports Second Quarter 2016 Financial And Operating Results 40

May 16, 2016: Coherus Biosciences Appoints Patrick O'Brien As Senior Vice President, Investor Relations 42

May 09, 2016: Coherus Biosciences Reports First Quarter 2016 Financial And Operating Results 43

Feb 29, 2016: Coherus BioSciences Reports Fourth Quarter and Year End 2015 Financial and Operating Results 45

Corporate Communications 47

Mar 27, 2017: Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development 47

Legal and Regulatory 48

Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 48

Clinical Trials 49

Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Coherus BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Coherus BioSciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Coherus BioSciences Raises USD55 Million in Series C Venture Financing 12

Coherus BioSciences Raises USD28 Million In Venture Financing 13

Coherus BioSciences Raises USD46.3 Million In Venture Financing 14

Baxter Amends Co-Development Agreement with Coherus Biosciences 14

Baxter International Enters Into Co-Development Agreement With Coherus Biosciences 15

Coherus BioSciences Enters into Licensing Agreement with Genentech 16

Coherus BioSciences Enters into Licensing Agreement with Selexis 17

Orox Pharma Enters into Licensing Agreement with Coherus BioSciences 18

Coherus BioSciences Enters Into Licensing Agreement With Daiichi Sankyo For Biosimilars 19

Coherus Biosciences Prices Public Offering of Shares for USD125 Million 20

Coherus Biosciences Plans to Raise up to USD100 Million in Public Offering of Shares 22

Coherus BioSciences Prices Public Offering of Shares for USD63 Million 23

Coherus BioSciences Raises USD10 Million in Private Placement of Shares 24

Coherus BioSciences Prices Public Offering of Shares for USD120 Million 25

Coherus BioSciences Raises USD92 Million in IPO of Shares 26

Coherus BioSciences Raises USD2.5 Million in Private Placement of Shares 28

Coherus BioSciences Receives Equity Investment from MX II Associate 28

Coherus BioSciences Raises USD100 Million in Private Placement of 8.2% Notes Due 2022 29

Coherus BioSciences Inc, Key Competitors 31

Coherus BioSciences Inc, Key Employees 32

Coherus BioSciences Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Coherus BioSciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com